ישראל -
עברית -
Ministry of Health
בסרמי 250 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
פייקומפה תרחיף לשתיה
eisai israel ltd., israel - perampanel as anhydrous - תרחיף - perampanel as anhydrous 0.5 mg / 1 ml - perampanel
ישראל -
עברית -
Ministry of Health
אייקוניקס ביו טק מסכת קונטור להבהרה ולחידוש העור עם קומפלקס הבהרה
מעבדות דר מלומד - מסכת פילינג לעור הפנים,הבהרה וחידוש עור הפנים,מסייע בהלבנת כתמי עור ופיגמנטציה
ישראל -
עברית -
Ministry of Health
דרפן- סרום להדגשת ולייצוב העור סביב העין
אלקליל בעמ - שיפור מראה העור
ישראל -
עברית -
Ministry of Health
פלאג'יל 250 מג טבליות
sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.
ישראל -
עברית -
Ministry of Health
אפיניטור 5 מג
novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*
ישראל -
עברית -
Ministry of Health
אפיניטור 10 מג
novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*